Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 2
2012 1
2013 2
2015 2
2017 1
2019 2
2021 1
2022 1
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Epidemiology of surgery associated acute kidney injury (EPIS-AKI): a prospective international observational multi-center clinical study.
Zarbock A, Weiss R, Albert F, Rutledge K, Kellum JA, Bellomo R, Grigoryev E, Candela-Toha AM, Demir ZA, Legros V, Rosenberger P, Galán Menéndez P, Garcia Alvarez M, Peng K, Léger M, Khalel W, Orhan-Sungur M, Meersch M; EPIS-AKI Investigators. Zarbock A, et al. Intensive Care Med. 2023 Dec;49(12):1441-1455. doi: 10.1007/s00134-023-07169-7. Epub 2023 Jul 28. Intensive Care Med. 2023. PMID: 37505258 Free PMC article.
A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response-Dependent Survival of Quiescent Cancer Cells.
Calvo V, Zheng W, Adam-Artigues A, Staschke KA, Huang X, Cheung JF, Nobre AR, Fujisawa S, Liu D, Fumagalli M, Surguladze D, Stokes ME, Nowacek A, Mulvihill M, Farias EF, Aguirre-Ghiso JA. Calvo V, et al. Clin Cancer Res. 2023 Dec 15;29(24):5155-5172. doi: 10.1158/1078-0432.CCR-23-1427. Clin Cancer Res. 2023. PMID: 37982738
PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors.
Stokes ME, Calvo V, Fujisawa S, Dudgeon C, Huang S, Ballal N, Shen L, Gasparek J, Betzenhauser M, Taylor SJ, Staschke KA, Rigby AC, Mulvihill MJ, Bose N, Lightcap ES, Surguladze D. Stokes ME, et al. Among authors: calvo v. Clin Cancer Res. 2023 Dec 1;29(23):4870-4882. doi: 10.1158/1078-0432.CCR-23-1182. Clin Cancer Res. 2023. PMID: 37733811 Free PMC article.
Left ventricular puncture during thoracentesis.
Farinas Lugo D, Chalasani P, Del Calvo V. Farinas Lugo D, et al. Among authors: del calvo v. BMJ Case Rep. 2019 Apr 8;12(4):e227613. doi: 10.1136/bcr-2018-227613. BMJ Case Rep. 2019. PMID: 30967447 Free PMC article.
Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors.
Calvo V, Surguladze D, Li AH, Surman MD, Malibhatla S, Bandaru M, Jonnalagadda SK, Adarasandi R, Velmala M, Singireddi DRP, Velpuri M, Nareddy BR, Sastry V, Mandati C, Guguloth R, Siddiqui S, Patil BS, Chad E, Wolfley J, Gasparek J, Feldman K, Betzenhauser M, Wiens B, Koszelak-Rosenblum M, Zhu G, Du H, Rigby AC, Mulvihill MJ. Calvo V, et al. Bioorg Med Chem Lett. 2021 Jul 1;43:128058. doi: 10.1016/j.bmcl.2021.128058. Epub 2021 Apr 23. Bioorg Med Chem Lett. 2021. PMID: 33895276 Free article.
Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments.
Fluegen G, Avivar-Valderas A, Wang Y, Padgen MR, Williams JK, Nobre AR, Calvo V, Cheung JF, Bravo-Cordero JJ, Entenberg D, Castracane J, Verkhusha V, Keely PJ, Condeelis J, Aguirre-Ghiso JA. Fluegen G, et al. Among authors: calvo v. Nat Cell Biol. 2017 Feb;19(2):120-132. doi: 10.1038/ncb3465. Epub 2017 Jan 23. Nat Cell Biol. 2017. PMID: 28114271 Free PMC article.
16 results